Results 161 to 170 of about 820,000 (258)

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić   +4 more
wiley   +1 more source

Other title: Kansas Insurance Department news release, 2004; Other title: Kansas Insurance Commissioner: for immediate release, 2004

open access: yes, 2004
application/pdf; Annual cumulation of 2004 issuesFelony Charges Filed Against Selden Insurance Agent Kansas Insurance Department Fraud Unit Cooperates with Sheridan County Attorney -- Praeger Announces Proposed Legislation Consumer Protection Provisions ...
Kansas. Insurance Department.
core  

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Other title: Kansas Insurance Department news release, 2000; Other title: Kansas Insurance Commissioner: for immediate release, 2000

open access: yes, 2000
April-May 2000; application/pdf; Annual cumulation of 2000 issuesClick-it Cricket program the key to Kansas exit from the Beltless Belt, Sebelius says -- Salina scam artist gets 27 months, Sebelius announces -- Kansas remains a great place for drivers ...
Kansas. Insurance Department.
core  

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Kansas Insurance Department, Commission and Superintendent - Annual Reports (1871-1999).

open access: yes, 1871
A centennial history of the Kansas Insurance Department appears at the beginning of the 101st Annual Report (1970/71) of the Department. Annual reports issued after 1999 can be found in the KGI Online Library separately under the Kansas Insurance ...
Kansas. Insurance Department.
core   +1 more source

Other title: Kansas Insurance Department news release

open access: yes, 2001
application/pdf Annual cumulation of 2001 issuesCosts of Storm Damage For Kansans Drastically Decrease In 2000 -- Sebelius Calls For Strong Leadership In State Of The State Response -- Sebelius Confirms Kaiser Permanente Is Pulling Out Of Kansas City ...
Kansas. Insurance Department.
core  

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy